We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current 0K6R market cap is 9.28B. The company's latest EPS is USD 3.3710 and P/E is 32.86.
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 1.05B | 1.13B | 1.49B | 1.89B | 2.36B |
| Operating Income | 163M | 102.5M | 249M | 250.9M | 570.5M |
| Net Income | 407.3M | 89.6M | 154.5M | 249.7M | 341.3M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 1.73B | 2.07B | 2.37B | 3.25B | 3.72B |
| Total Liabilities | 608.5M | 698.5M | 660.9M | 1.02B | 1.13B |
| Total Equity | 1.13B | 1.37B | 1.71B | 2.23B | 2.59B |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 228.5M | 256.5M | 339.4M | 389.9M | 595.4M |
| Investing | 4.1M | -130.2M | -177.1M | -467.1M | -126.8M |
| Financing | -157.8M | 27.4M | -234.3M | 65.3M | -486.7M |
| Market Cap | 9.28B |
| Price to Earnings Ratio | 32.86 |
| Price to Sales Ratio | 4.76 |
| Price to Cash Ratio | 48.14 |
| Price to Book Ratio | 4.33 |
| Dividend Yield | - |
| Shares Outstanding | 101.25M |
| Average Volume (1 week) | 120 |
| Average Volume (1 Month) | 227 |
| 52 Week Change | 0.00% |
| 52 Week High | 91.67 |
| 52 Week Low | 91.67 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Neurocrine Biosciences Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.neurocrine.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
